You are here


Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Primary tabs

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.
NIH Reference Number
Product Type
  • middle east respiratory syndrome
  • MERS
  • coronavirus
  • antibody
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines.

The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection.  Researchers at the NCI have developed human antibodies that target MERS-CoV.  Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralizing the virus as demonstrated in a pseudovirus assay.

Potential Commercial Applications
  • Antibody-based therapeutics for treatment of MERS-CoV infection
Competitive Advantages
  • No vaccine or other biologic therapy is available, and this antibody provides high binding (sub-nanomolar) affinity, and relative safety with long half-lives.

Dimiter Dimitrov, Tianlei Ying (NCI), Tina Ju (NCI), Kwok Yuen

Development Stage

Zaki AM, et al. [PMID 23075143]

Zhu Z, et al. [PMID 18271743]

Zhu Z, et al. [PMID 17620608]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 61/892,750, Filed 18 Oct 2013
Therapeutic Area
Wednesday, May 30, 2018